KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.

Satoru Kitazono, Akira Ono, Tetsuji Kawamura, Osamu Hataji, Hiroshi Tanaka, Shingo Matsumoto, Naohiro Watanabe, Hiromi Nagashima, Masahide Oki, Michiko Takahashi, Tomoko Anazawa, Takahiro Shirai, Aimi Yamashita, Honeylet Wortman-Vayn, Archan Bhattacharya, Trishala Agrawal, Mahadi Baig, Roland E Knoblauch, Hidetoshi Hayashi

Cancer Sci 116(11) 3139-3148

PMID40922529
PMCIDPMC12580869
DOI10.1111/cas.70180
发表日期2025-09-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIGURE 1:非 KM 图;FIGURE 2:非 KM 图;FIGURE 3:瀑布图;FIGURE 4:非 KM 图;FIGURE 5:非 KM 图。
摘要

摘要

Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (EGFR Exon 20ins) are the third most common mutations in non-small cell lung cancer (NSCLC) and are associated with a poorer prognosis and resistance to conventional EGFR-tyrosine kinase inhibitors. This subpopulation analysis of the open-label phase 3 trial (PAPILLION) evaluates the efficacy and safety of amivantamab-chemotherapy versus chemotherapy among Japanese patients with locally advanced or metastatic NSCLC with EGFR Exon 20ins mutation (ClinicalTrials.gov, NCT04538664). Patients were randomized 1:1 to either intravenous amivantamab plus carboplatin/pemetrexed chemotherapy or chemotherapy alone. The primary endpoint was progression-free survival (PFS) by blinded independent central review; the secondary endpoints included objective response rate, duration of response, PFS after first subsequent therapy, overall survival, and safety. The overall population (n = 308) included 34 Japanese patients (amivantamab-chemotherapy, n = 19; chemotherapy, n = 15). Median PFS was 15.5 (95% CI 8.0, NE) months with amivantamab-chemotherapy compared with 5.6 (95% CI 3.0, 7.0) months (HR = 0.22 [0.09, 0.53]) for chemotherapy alone. Improvements in secondary endpoints were also greater in the amivantamab-chemotherapy arm than the chemotherapy arm. The predominant adverse events associated with amivantamab-chemotherapy were reversible hematologic and EGFR-related toxic effects; 2 of 19 patients discontinued all study agents due to treatment-emergent adverse events. Efficacy and safety results in this Japanese subpopulation were consistent with those in the overall population and support the first-line use of amivantamab-chemotherapy in this setting. Early identification of patients with EGFR Exon 20ins mutations, preferably with more sensitive next-generation sequencing-based methods, is important to ensure appropriate patient access to amivantamab-chemotherapy. Trial Registration: ClinicalTrials.gov, NCT04538664.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Patient disposition.
非 KM Figure
FIGURE 2Primary endpoint of PFS by BICR in Japanese subpopulation.
非 KM Figure
FIGURE 3Waterfall plots of the best percent change from baseline in target lesions in the (A) chemotherapy group and in the (B) amivantamab–chemotherapy group. Abbreviation: SoD, sum of the longest diameters.
非 KM Figure
FIGURE 4Progression‐free survival after first subsequent therapy in the Japanese subpopulation.
非 KM Figure
FIGURE 5Overall survival at the interim analysis in the Japanese subpopulation.
非 KM Figure